Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation.
Nicole P DaukshusAnthony CirincioneMolly SiverSherry MathewBinni KunvarjeeAmelia ChanJaap Jan BoelensSusan K SeoGenovefa A PapanicolaouNancy A KernanPublished in: Journal of the Pediatric Infectious Diseases Society (2022)
There are limited data for letermovir as primary cytomegalovirus (CMV) prophylaxis in patients less than 18 years of age. We report 9 adolescent patients who received letermovir following hematopoietic cell transplantation. No patients developed clinically significant CMV while taking letermovir. Letermovir was well tolerated and efficacious in preventing CMV infections.